169 related articles for article (PubMed ID: 18644960)
1. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Lounis N; Gevers T; Van Den Berg J; Andries K
Antimicrob Agents Chemother; 2008 Oct; 52(10):3568-72. PubMed ID: 18644960
[TBL] [Abstract][Full Text] [Related]
2. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
[TBL] [Abstract][Full Text] [Related]
5. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
6. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
7. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
9. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
10. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
[TBL] [Abstract][Full Text] [Related]
11. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently.
Gelber R; Andries K; Paredes RM; Andaya CE; Burgos J
Antimicrob Agents Chemother; 2009 Sep; 53(9):3989-91. PubMed ID: 19596891
[TBL] [Abstract][Full Text] [Related]
12. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility.
Nuermberger E; Mitchison DA
Am J Respir Crit Care Med; 2009 Jan; 179(1):2-3. PubMed ID: 19098156
[No Abstract] [Full Text] [Related]
15. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Jindani A; Doré CJ; Mitchison DA
Am J Respir Crit Care Med; 2003 May; 167(10):1348-54. PubMed ID: 12519740
[TBL] [Abstract][Full Text] [Related]
16. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
17. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834
[TBL] [Abstract][Full Text] [Related]
18. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
19. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
20. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
Gosling RD; Uiso LO; Sam NE; Bongard E; Kanduma EG; Nyindo M; Morris RW; Gillespie SH
Am J Respir Crit Care Med; 2003 Dec; 168(11):1342-5. PubMed ID: 12917230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
